Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myriad Genetics

5.09
+0.17003.46%
Post-market: 5.110.0200+0.39%19:04 EDT
Volume:1.69M
Turnover:8.58M
Market Cap:469.18M
PE:-4.55
High:5.17
Open:4.93
Low:4.93
Close:4.92
Loading ...

Myriad Genetics Down Over 36%, On Track for Largest Percent Decrease Since November 2019 -- Data Talk

Dow Jones
·
07 May

Myriad Genetics Is Maintained at Neutral by UBS

Dow Jones
·
07 May

Myriad Genetics Price Target Cut to $10.00/Share From $19.00 by Raymond James

Dow Jones
·
07 May

Stock Track | Myriad Genetics Plummets 28.95% on Weak Q1 Results, Disappointing Outlook, and Analyst Downgrades

Stock Track
·
07 May

Traders Weigh Tariff News Ahead of Fed Decision, Lifting US Equity Futures Pre-Bell

MT Newswires Live
·
07 May

Myriad Genetics Inc : JP Morgan Cuts Target Price to $6 From $12

THOMSON REUTERS
·
07 May

Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22

MT Newswires Live
·
07 May

Stock Track | Myriad Genetics Plummets 17.47% in Pre-market Following Disappointing Q1 Results and Weak 2025 Outlook

Stock Track
·
07 May

Stock Track | Myriad Genetics Plummets 17.47% in Pre-market Following Disappointing Q1 Results and Weak 2025 Outlook

Stock Track
·
07 May

Stock Track | Myriad Genetics Plunges 13.34% Following Disappointing Q1 Results and Weak 2025 Outlook

Stock Track
·
07 May

Myriad Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Stock Track | Myriad Genetics Plunges 18% After Hours Following Disappointing Q1 Results and Weak Outlook

Stock Track
·
07 May

Stock Track | Myriad Genetics Plummets 5.78% Following Disappointing Q1 Results with $29 Million Operating Loss

Stock Track
·
07 May

Stock Track | Myriad Genetics Plummets 5.78% Following Disappointing Q1 Results with $29 Million Operating Loss

Stock Track
·
07 May

Myriad Genetics Q1 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $195.90M Miss $200.56M Estimate

Benzinga
·
07 May

BRIEF-Myriad Genetics Q1 Operating Income USD -29 Million

Reuters
·
07 May

Myriad Genetics Inc Outlook FY 2025 Adj EPS $-0.02 - $0.02

THOMSON REUTERS
·
07 May

Myriad Genetics Inc Outlook FY 2025 REV $807 Mln - $823 Mln

THOMSON REUTERS
·
07 May

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

GlobeNewswire
·
30 Apr

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

GlobeNewswire
·
29 Apr